Lacimen

Lacidipine, the active ingredient in Lacimen, is a calcium channel blocker presented as an oral tablet for oral use. It selectively inhibits L‑type calcium channels in vascular smooth muscle, producing vasodilation and helping to control high blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Lacimen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under GMP conditions.

Lacidipine is used to treat conditions related to elevated vascular resistance and high blood pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: lowers elevated systolic pressure in older adults. - Secondary hypertension: assists in blood pressure control when hypertension is due to other causes, as part of combination therapy.

Lacidipine may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause fainting. - Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmias: irregular heart rhythms. - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.

When prescribing lacidipine, clinicians should consider several precautionary measures to ensure safe use.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution and adjust dose if needed. - Elderly patients: start at low dose and monitor for dizziness. - Concomitant antihypertensives: assess for additive blood pressure lowering. - Severe aortic stenosis: contraindicated due to risk of hypotension. - Store at room temperature: keep in original container, protect from moisture.

Lacidipine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Grapefruit juice: can markedly raise drug concentration. - Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance blood pressure‑lowering effect. - Beta‑blockers: additive hypotensive effect. - NSAIDs: may blunt antihypertensive response. - ACE inhibitors or ARBs: monitor renal function and potassium levels.